Lipoprotein(a), or Lp(a), remains an important and independent risk factor for ASCVD, and clinicians and patients should continue to measure it.
In the latest Lipid Insights episode, host Peter H. Jones, MD, MNLA is joined by leading Lp(a) experts Michael B. Boffa, PhD, and Marlys L. Koschinsky, PhD, FNLA, to react to the Lp(a)HORIZON trial results and discuss what’s next for Lp(a) in cardiovascular prevention.
Watch on YouTube or listen on your favorite podcast platform.
▶️ youtu.be/iaqsKJHuLIM#Lipidology#Lipoproteina#Lpa#CardiovascularPrevention
👉 MUST READ; A landmark EAS Statement in the post-Lp(a)HORIZON era in @ATHjournal
☝️The European Atherosclerosis Society @society_eas delivers a timely, evidence-based message following the neutral results of Lp(a)HORIZON.
1️⃣ 78% Lp(a) reduction ≠ cardiovascular benefit.
We must distinguish a causal risk factor from a validated therapeutic target.
2️⃣ Lp(a) remains a major cardiovascular risk factor.
Measure it at least once in every adult. Family screening remains essential.
3️⃣ LDL-C lowering is our strongest actionable strategy.
Intensive control of LDL-C and other risk factors can mitigate Lp(a)-associated risk.
4️⃣ Timing may be everything.
Can a few years of treatment reverse decades of cumulative atherogenic exposure?
5️⃣ The science is far from over. Ongoing RCTs with different Lp(a)-lowering agents are essential.
☝️My key takeaway: A negative trial should change our assumptions, not replace scientific evidence with speculation.
☝️ Measure Lp(a). Lower LDL-C. Control global risk.
Keep testing hypotheses with RCTs.
🔗 atherosclerosis-journal.com/…@BNordestgaard@ProfKausikRay@MeralKayikcoglu@KronenbergLab@j_rvl@SamiaMoraMD
The primary results from the Lp(a)HORIZON trial were presented at #AHA26 in Chicago on November 7. Although pelacarsen lowered lipoprotein(a) [Lp(a)] levels, the trial did not reduce the risk of major adverse cardiovascular events (MACE).
In the latest Lipid Insights episode, host Peter H. Jones, MD, MNLA sits down with two leading Lp(a) experts, Michael B. Boffa, PhD, and Marlys L. Koschinsky, PhD, FNLA, to react to the results and discuss what’s next for Lp(a) in cardiovascular prevention.
Watch on YouTube or listen on your favorite podcast platform.
▶️ youtu.be/iaqsKJHuLIM#Lipidology#Lipoproteina#Lpa#CardiovascularPrevention
One key fact that everyone should know about Lp(a):
Comprehensive cardiometabolic screening and management using just lipids and basic biometrics is incomplete without also considering a one-time Lp(a) value for the individual.
Lp(a) + lipoproteins + IR + glycemic status + noninvasive imaging results + inflammation + biometrics + clinical history
Dr Dean Karalis and @dan_soffer kicking off the @cvi_phila program on Lp(a) with @MarlysLPA!
Excited to represent @FamilyHeartFdn at this important program!
Leading cause of death in Philly? Heart disease!
The more we learn about Lp(a) the more we have to worry about the 1 out of 5 people who have elevations. Will significantly lowering Lp(a) solve the aortic valve deterioration? For those of you with elevated Lp(a) make sure your clinicians are closely watching the heart valves. Periodic echos for all? pubmed.ncbi.nlm.nih.gov/3901…@nationallipid@society_eas@FamilyHeartFdn@escardio#KnowLpa
Our latest review article on Lp(a), which actually made the cover of Biochemical Journal! As before this journal, we go into some depth on the more basic molecular details of Lp(a). Enjoy!
@MarlysLPAportlandpress.com/biochemj/a…